Barclays Cuts Rating on Pacira BioSciences Post Generic Exparel Nod

Wednesday, 3 July 2024, 18:32
Barclays downgrades Pacira BioSciences (PCRX) in response to the FDA's approval of a generic version of Exparel, the company's leading medication. This development is set to have significant implications on the company's revenue and market position. Learn more about the impact of this downgrade on PCRX in the financial markets.
Seeking Alpha
Barclays Cuts Rating on Pacira BioSciences Post Generic Exparel Nod

Barclays Downgrades Pacira BioSciences

Barclays has decided to lower its rating on Pacira BioSciences (PCRX) following the FDA's approval of a generic alternative to Exparel, the company's primary product.

Impact on Company's Best-Selling Drug

The approval of the generic Exparel will directly affect the market shares and revenue of Pacira BioSciences.

Read more to explore the potential implications of this development on PCRX's financial performance and market standing.

Do you want to advertise here? Contact us

Related posts

Do you want to advertise here? Contact us
Do you want to advertise here? Contact us
Newsletter

We carefully select news from the world of finance and publish it for our users. We understand the importance of reliable and up-to-date information for people in the financial world. Do you want to receive news in a convenient format and always have it at hand — subscribe to our newsletter and make your analytical work more effective.

Subscribe